BioCentury | Oct 11, 2018
Financial News

Polaris, Arch co-lead series A for MIT spinout Glympse

With $22 million in new series A funding, Glympse Bio Inc. (Cambridge, Mass.) plans to start clinical testing by mid-2019 of its bio-engineered diagnostic for non-alcoholic steatohepatitis (NASH). Glympse is developing injectable bio-engineered activity sensors...
BioCentury | Oct 9, 2018
Financial News

Polaris, Arch co-lead series A for MIT spinout Glympse

With $22 million in new series A funding, Glympse Bio Inc. (Cambridge, Mass.) plans to start clinical testing by mid-2019 of its bio-engineered diagnostic for non-alcoholic steatohepatitis (NASH). Glympse is developing injectable bio-engineered activity sensors...
BioCentury | Sep 8, 2018
Product Development

Data distribution

...of patients,” he said. TransCelerate SVP of Global Operations Janice Chang told BioCentury that an undisclosed pharmaceutical company...
BioCentury | Aug 10, 2018
Financial News

Sensyne proposes London IPO

...patient care through the development of new digital tools. The company has partnered with one undisclosed pharmaceutical company...
BioCentury | Aug 7, 2018
Financial News

Sensyne proposes London IPO

...patient care through the development of new digital tools. The company has partnered with one undisclosed pharmaceutical company...
BioCentury | Mar 7, 2018
Translation in Brief

Model perpetrators

...as leukopenia and myelosuppression, for cancer therapies. The group has a consultancy collaboration with an undisclosed pharmaceutical company...
BioCentury | Feb 6, 2018
Politics & Policy

EU court upholds EMA's decisions on transparency

...superior. In a second case, PTC Therapeutics Inc. (NASDAQ:PTCT) contested EMA's decision to grant an undisclosed pharmaceutical company...
BioCentury | Jul 7, 2017
Company News

Arrien out-licenses RORgammaT series and autoimmune candidate ARN-6039

...Arrien Pharmaceuticals LLC (Salt Lake City, Utah) granted an undisclosed pharmaceutical company worldwide rights to ARN-6039 and a...
BioCentury | Mar 2, 2017
Company News

Undisclosed company gets rights to Isogenica llamdA library

...Isogenica granted an undisclosed pharmaceutical company rights to its family of llamdA camelid single-domain antibody libraries for the...
BioCentury | Feb 3, 2017
Company News

Abilita deal

...Abilita partnered with an undisclosed pharmaceutical company to use its EMP membrane protein evolution platform to discover and...
Items per page:
1 - 10 of 93
BioCentury | Oct 11, 2018
Financial News

Polaris, Arch co-lead series A for MIT spinout Glympse

With $22 million in new series A funding, Glympse Bio Inc. (Cambridge, Mass.) plans to start clinical testing by mid-2019 of its bio-engineered diagnostic for non-alcoholic steatohepatitis (NASH). Glympse is developing injectable bio-engineered activity sensors...
BioCentury | Oct 9, 2018
Financial News

Polaris, Arch co-lead series A for MIT spinout Glympse

With $22 million in new series A funding, Glympse Bio Inc. (Cambridge, Mass.) plans to start clinical testing by mid-2019 of its bio-engineered diagnostic for non-alcoholic steatohepatitis (NASH). Glympse is developing injectable bio-engineered activity sensors...
BioCentury | Sep 8, 2018
Product Development

Data distribution

...of patients,” he said. TransCelerate SVP of Global Operations Janice Chang told BioCentury that an undisclosed pharmaceutical company...
BioCentury | Aug 10, 2018
Financial News

Sensyne proposes London IPO

...patient care through the development of new digital tools. The company has partnered with one undisclosed pharmaceutical company...
BioCentury | Aug 7, 2018
Financial News

Sensyne proposes London IPO

...patient care through the development of new digital tools. The company has partnered with one undisclosed pharmaceutical company...
BioCentury | Mar 7, 2018
Translation in Brief

Model perpetrators

...as leukopenia and myelosuppression, for cancer therapies. The group has a consultancy collaboration with an undisclosed pharmaceutical company...
BioCentury | Feb 6, 2018
Politics & Policy

EU court upholds EMA's decisions on transparency

...superior. In a second case, PTC Therapeutics Inc. (NASDAQ:PTCT) contested EMA's decision to grant an undisclosed pharmaceutical company...
BioCentury | Jul 7, 2017
Company News

Arrien out-licenses RORgammaT series and autoimmune candidate ARN-6039

...Arrien Pharmaceuticals LLC (Salt Lake City, Utah) granted an undisclosed pharmaceutical company worldwide rights to ARN-6039 and a...
BioCentury | Mar 2, 2017
Company News

Undisclosed company gets rights to Isogenica llamdA library

...Isogenica granted an undisclosed pharmaceutical company rights to its family of llamdA camelid single-domain antibody libraries for the...
BioCentury | Feb 3, 2017
Company News

Abilita deal

...Abilita partnered with an undisclosed pharmaceutical company to use its EMP membrane protein evolution platform to discover and...
Items per page:
1 - 10 of 93